Temasek subsidiary Ion to earn up to $1b by paring stake in South Korean firms

Temasek subsidiary Ion to earn up to $1b by paring stake in South Korean firms

Photo: Celltrion's Facebook page

Ion Investments, which is controlled by Temasek Holdings of Singapore, is selling part of its stake in South Korean pharmaceutical company Celltrion and distributor Celltrion Healthcare, IFR reported on Tuesday, citing a term sheet.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter